Trial
NCT04892446
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Multiple Myeloma
Intervention
Magrolimab
Why stopped
This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-02